Systimmune Inc., founded in 2014 in Redmond, WA, is a bio-pharmaceutical company specializing in the development of novel bi-specific and tri-specific antibodies, as well as antibody-drug conjugates (ADCs) for cancer treatment. The company focuses on systematically intervening in the solid tumor micro-environment to either directly attack tumors or activate the immune system. Led by experienced immuno-oncology scientists, Systimmune leverages advanced technology platforms to create world-class antibody-based drug therapies.
SystImmune is hiring a Director to lead its AI-enabled small molecule design function. The role involves defining, building, and leading the function, and applying advanced AI methodologies to generate novel small molecules and predict target interactions.
Systimmune Inc., founded in 2014 in Redmond, WA, is a bio-pharmaceutical company specializing in the development of novel bi-specific and tri-specific antibodies, as well as antibody-drug conjugates (ADCs) for cancer treatment. The company focuses on systematically intervening in the solid tumor micro-environment to either directly attack tumors or activate the immune system. Led by experienced immuno-oncology scientists, Systimmune leverages advanced technology platforms to create world-class antibody-based drug therapies.
Isomorphic Labs